reports
- Stephane Foucaud
AUCTUS ON FRIDAY - 03/05/2024
AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; target price of A$0.75 per share: Raising new equity to fund a high impact activity programme – ADX has raised A$13.5 mm of new equity priced at A$0.105 per share. One free-attaching option will be issued for evert two placement shares with an exercise price of A$0.15 per share and an expiry date of 08/05/2026. The proceeds from the raise will fund (1) the production testing of the 450 m gas column encountered at ...
GALP GALP ENERGIA SGPS SA CLASS B
GTE GRAN TIERRA ENERGY
EGY VAALCO ENERGY INC.
OMV OMV AG
TXP TOUCHSTONE EXPLORATION
SEI. SINTANA ENERGY
CHAR CHARIOT OIL & GAS
PEN PANORO ENERGY ASA
DELT DELTIC ENERGY
CNE CANACOL ENERGY LTD
ZPHR ZEPHYR ENERGY
JSE JADESTONE ENERGY
AXL. ARROW EXPLORATION LTD
I3E I3 ENERGY
TRIN TRINITY CAPITAL INC
CEQ CRITERIUM ENERGY LTD.
ADX ADX ENERGY LTD
BWEFF BW ENERGY LTD
LNGE LNG ENERGY GROUP CORP.
SHELL ROYAL DUTCH SHELL
Myriad Genetics to Release First Quarter 2024 Financial Results on May...
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 Management will also participate in four upcoming investor healthcare conferences SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first...
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to P...
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor 80% of people diagnosed with anxiety, depression report losing years or decades of time SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest Mental Health Monitor, a nationwide survey from , Inc. (NASDAQ:MYGN), a leader in genetic testing and precis...
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High P...
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a 1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA lab...
Myriad Genetics Research Shows Reduction in Hospitalizations for Patie...
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the . “We are encouraged by the initial results of this study that sh...
Myriad Genetics Announces Foundational Patent Granted for Molecular Re...
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA...
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040. The patent further covers technology for improv...
- Stephane Foucaud
AUCTUS ON FRIDAY - 15/03/2024
AUCTUS PUBLICATIONS ________________________________________ Chariot (CHAR LN)C; target price of £0.50 per share: Feasibility study as a first step to unlocking a mega green hydrogen project – The feasibility study for the green hydrogen “Project Nour” has now been presented to the government of Mauritania. Chariot holds a 50% interest in the project and TotalEnergies is a partner. Mauritania benefits from an ideal geography for wind and solar energy. The 10 GW project will be developed in sever...
GTE GRAN TIERRA ENERGY
GPRK GEOPARK
EGY VAALCO ENERGY INC.
GENL GENEL ENERGY
ENI ENI S.P.A.
SEI. SINTANA ENERGY
CHAR CHARIOT OIL & GAS
MAHA A MAHA ENERGY
SLE SAN LEON ENERGY
ZPHR ZEPHYR ENERGY
SEY AFENTRA (PREVIOUSLY
BNL STERLING ENERGY)
LNGE BLUE STAR HELIUM LTD
LNG ENERGY GROUP CORP.
- Research Team ACF
BrainStorm Cell Therapeutics Inc Core Investment Case 13032024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is a biotechnology company focused on developing autologous mesenchymal stem cell (MSC) therapies for the treatment of neurodegenerative diseases – BCLI’s primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig’s). BCLI’s’s proprietary technology platform, NurOwnTM, stimulates Mesenchymal Stem Cells to emit neurotrophic factors (MSC-NTF), which promote the survival of neurons across multiple disease states.
Fleetcor Technologies Inc: 1 director
A director at Fleetcor Technologies Inc sold/sold after exercising options 7,004 shares at 290.455USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Finan...
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance Highlights: Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek® volume.Full-year 2023 revenue of $753 million, grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek), Prolaris (21%), Pharmacogenomics (9%), and Hereditary Cancer (7%).Fourth quarter GAAP operati...
Myriad Genetics and National Cancer Center Hospital East in Japan Coll...
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-S...
- Stephane Foucaud
AUCTUS ON FRIDAY - 23/02/2024
AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; target price of £A$0.65 per share: Drilling update in Austria - Drilling operations at the high impact Welchau prospect are now expected to commence on 24 February with a duration of ~39 days. ADX will now use the RED E200 rig instead of RED E202. Arrow Exploration (AXL LN/CN)C; target price of £0.60 per share: Successful appraisal drilling expected to boost reserves – The CN-5 well encountered 45 feet of Ubaque ...
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial...
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Management will also participate in two upcoming healthcare conferences SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company...
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Me...
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she will support internal and external efforts to increase access to, and equ...
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid...
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. Myriad’s Test, which was also offered by IPG as TheraMap®: Solid Tumor, analyzes a...
Myriad Genetics Names George Daneker Jr., MD, as President and Chief C...
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laborator...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. The acquisition is expected to close on Febru...
Myriad Genetics Applauds New Germline Testing Guideline for Patients w...
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer. The new offers multi-pronged, evidence-based clinical practice recommendations. Among the guidance includes: All patients with a current or previous diagnosis of invasive breast c...
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Confe...
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST. The presentation will be available through a live webcast in the investor relations section of Myriad’s website at . An archived edition of the presentation will be available later that day. About Myriad Genetics Myriad G...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.